| Diabetes Mellitus, Non-Insulin-Dependent

Inpefa vs Rybelsus

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.

Deep comparison between: Inpefa vs Ozempic with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsOzempic has a higher rate of injection site reactions vs Inpefa based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Ozempic but not Inpefa, including UnitedHealthcare

Category

Inpefa

Ozempic

At A Glance

RouteOral

FrequencyDaily

ClassSGLT1/SGLT2 inhibitor

RouteOral

FrequencyDaily

ClassGLP-1 receptor agonist

Indications

Heart failure
Diabetes Mellitus, Non-Insulin-Dependent
Chronic Kidney Diseases

Diabetes Mellitus, Non-Insulin-Dependent

Dosing

Heart failure, Diabetes Mellitus, Non-Insulin-Dependent, Chronic Kidney Diseases 200 mg orally once daily, not more than one hour before the first meal; titrate after at least 2 weeks to 400 mg once daily as tolerated; down-titrate to 200 mg as necessary.

Diabetes Mellitus, Non-Insulin-Dependent Starting dose 1.5 mg orally once daily for 30 days (not effective for glycemic control); escalate to 4 mg once daily days 31-60; maintain at 4 mg or increase to 9 mg once daily if additional glycemic control is needed. Take on an empty stomach in the morning with up to 4 oz water; wait at least 30 minutes before eating, drinking, or taking other oral medications.

Contraindications

History of serious hypersensitivity reaction to INPEFA

Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Prior serious hypersensitivity reaction to semaglutide or any excipient in OZEMPIC tablets

Drug Interactions

480View drug interactions

943View drug interactions

Adverse Reactions

Most common (>=2%) Urinary tract infection, volume depletion, diarrhea, hypoglycemia, dizziness, genital mycotic infection

Serious Diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, hypoglycemia with insulin and insulin secretagogues, necrotizing fasciitis of the perineum, genital mycotic infections

Most common (>=5%) nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation

Serious risk of thyroid C-cell tumors, acute pancreatitis, diabetic retinopathy complications, hypoglycemia with concomitant insulin secretagogues or insulin, acute kidney injury due to volume depletion, severe gastrointestinal reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation

Postmarketing acute and necrotizing pancreatitis, ileus, intestinal obstruction, anaphylaxis, angioedema, rash, urticaria, cholecystitis, cholelithiasis requiring cholecystectomy, dizziness, dysesthesia, dysgeusia, headache, pulmonary aspiration, acute kidney injury, alopecia

Pharmacology

Sotagliflozin is a dual inhibitor of SGLT2 and SGLT1; SGLT2 inhibition reduces renal reabsorption of glucose and sodium (lowering cardiac pre- and afterload and downregulating sympathetic activity), while SGLT1 inhibition reduces intestinal absorption of glucose and sodium.

Semaglutide is a GLP-1 receptor agonist (GLP-1 analogue with 94% sequence homology to human GLP-1) that selectively binds to and activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion and inhibiting glucagon secretion to lower blood glucose, with a minor delay in early postprandial gastric emptying; its long half-life results from albumin binding and stabilization against DPP-4 degradation.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Inpefa